DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Spironolactone in Patients With Single Ventricle Heart

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Congenital Disorders

Intervention: Spironolactone (drug) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
William T Mahle, MD, Principal Investigator, Affiliation: Emory University
Arshed Quyyumi, MD, Principal Investigator, Affiliation: Emory University
Wendy M Book, MD, Principal Investigator, Affiliation: Emory University
Michael E McConnell, MD, Principal Investigator, Affiliation: Emory University

Summary

Ultrasound is a technique that can provide images of the blood vessels such as arteries. The size of the arteries, such as the main blood vessel in the arm, can change under different conditions. Using ultrasound we can see how arteries change with movement or even drugs. We want to use ultrasound to see how blood vessels look in patients with Congestive Heart Failure (CHF) and to also see how a drug called Spironolactone, commonly prescribed for patients with this disease, effects blood vessel function in patients with congestive heart failure. This information may be used to change the standard of care for patients with heart failure especially if we show that Spironolactone has a positive effect on vessel function in patients with CHF.

Clinical Details

Official title: Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change in Flow Mediated Dilation

Secondary outcome:

Change in BNP

Change in Form Assay

Change in TNF Alpha

Change in Cytotkine Panels

Change in 6 Minute Walk Test

Drawn and Conducted at Baseline and 4-5 Weeks After Initial Study.

Detailed description: Spironolactone The starting dose of spironolactone is 1 mg/kg/day. After two weeks this dose will be doubled to the same maximum dose (2/mg/kg/day) as in RALES. If side effects occur or plasma urea and electrolytes became deranged the dose will be halved. Patients unable to tolerate the minimum dose will be withdrawn. Measurement of serum electrolytes will occur at baseline, at two weeks, and at time of repeat evaluation. Endothelial Function Subjects with single ventricle will have an evaluation of endothelial function: 1. At baseline 2. On spironolactone- 4-5 weeks after initial study. Imaging protocol: The diameter of the brachial artery will be measured from two-dimensional ultrasound images, using a 12 MHz linear array transducer and an Accuson Sequoia system (Accuson, Mountainview, California). Measurements of the brachial artery will be obtained: 1. In a resting state 2. During limb ischemia 3. In response to reactive hyperemia 4. At rest Reactive hyperemia will be induced by inflating a standard blood pressure cuff to 50 mm Hg above the systolic blood pressure for 4. 5 minutes and then deflating the cuff. After data collection, the DICOM-formatted images will be transferred to a PC for investigator-blinded measurement of brachial artery diameter using image analysis software (Brachial Tools 3. 1, Medical Imaging Applications, Iowa). Measurement of prognostic markers: Blood samples Plasma beta-type natriuretic peptide, form assay, TNF alpha and a Cytokine panel will be drawn at base line and at the final 4-5 week visit for this study. Samples will be collected between 11 am and 1 pm after 30 minutes' supine rest. The samples

will be centrifuged and plasma stored at - 70°C (peptides) or -20°C (other samples). Plasma

[beta]-type natriuretic peptide (BNP) samples will be collected into EDTA and aprotonin and measured by radioimmunoassay 6-minute walk test. A 6-minute walk test will be performed at the first visit and the last visit. During this test, signs and symptoms will be recorded (i. e. chest pain and shortness of breath) to determine toleration of daily activity. A doctor or nurse will conduct this test and the patient will be provided the opportunity to stop or rest if symptoms become severe. Outcome measures The primary outcome measure will be the change in flow mediated dilation (during reactive hyperemia). This will be expressed as a percentage. Secondary outcome measures will include changes in BNP, Form assay, TNF alpha, Cytokine panels and the 6-minute walk test. Statistical analysis We and others have previously shown that asymptomatic patients with the Fontan operation have a mean flow-mediated dilation of approximately 4% compared to 8-9% in controls. In order to detect a 25% change in FMD, with a power of 0. 80, the current study would require a patient population of 13 cases. There are currently over 40 patients with single ventricle who are followed in the adult congenital clinic at Emory University. We plan on enrolling 20 patients into this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Single Ventricle Subjects

- >17 years

- have undergone Fontan Procedure

Exclusion Criteria:

- History of smoking

- Diabetes mellitus

- Renal failure (serum creatinine > 2. 5 mg/dl)

- Recovering spironolactone for maintenance therapy

- History of hyperkalemia (serum potassium> 5. 5 mEq/L)

Locations and Contacts

Emory Clinic, Atlanta, Georgia 30322, United States
Additional Information

Related publications:

Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.

Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J. 1995 Sep;74(3):247-53.

Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 1997 Aug;30(2):325-33. Review.

Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 1993 Sep;22(3):854-8.

Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000 Jan;35(1):60-6.

Gidding SS, Rocchini AP, Moorehead C, Schork MA, Rosenthal A. Increased forearm vascular reactivity in patients with hypertension after repair of coarctation. Circulation. 1985 Mar;71(3):495-9.

Yang SG, Rychik J. Mesenteric blood flow patterns: A link to protein-losing enteropathy after the Fontan operation. Circulation 1999;100-18:A3583.

Starting date: November 2004
Last updated: December 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017